Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• Colon cancer which includes rectal and colorectal adenocarcinoma, primary or metastatic adenocarcinoma, and the like, is a major health concern today in terms of disease incidence. It has been estimated that one out of twenty-five Americans will develop some form of colon cancer during the course of his lifetime. Sugarbaker, P.H. et al . , in Cancer, DeVita, V.T., et al . (Eds.), Lippincott Publ. Philadelphia, pp. 795-884 (1985) .
• 5- fluorouracil 5- fluorouracil
• Chemotherapy with 5-FU has been used in patients with metastases to the liver, but temporary improvement is observed in only 25 percent or less of such cases, and the overall, survival is not significantly affected.
• LaMont, J.T. and Isselbacher, K. in Harrison ' s Principles of Internal Medicine (10th ed.) McGraw-Hill, New York, p. 1764, (1983) .
• 5-FU no other drugs or combination therapy has been convincingly shown to be more effective.
• Drug therapies have also been evaluated with respect to treating human cancer, e.g., human colon cancer xenograft lines, in which human tumors are serially heterotransplanted into immunodeficient, so call "nude” mice, and the mice then tested for their responsiveness to a specific drug. Giovanella, B.C., et al . , Cancer 5(7) :1146 (1983) .
• the data obtained in these studies strongly support the validity of heterotransplanted human tumors, including colon tumors, into immunodeficient mammals, such as "nude” mice, as a predictive model for testing the effectiveness of anticancer agents.
• Miyasaka et al disclose 10-substituted camptothecin derivatives and process for their preparation.
• the 10- substituted camptothecin derivatives are said to possess anti-tumor activity with reduced or slight toxicity in comparison to the parent camptothecin compound.
• Miyasaka et al . do not disclose specific tumor targets nor do they indicate what level of reduced or slight toxicity is achieved by using their 10-substituted camptothecin compounds .
• the enzyme, human topoisomerase I has been examined in various human cancers, e. g. , leukemia, lymphoma. Potmesil M. et al . , Cancer Res . 48:3537 (1988) .
• Human topoisomerase I is known to be a onomeric protein with an apparent molecular weight of 100,000 daltons. The swivel-like function of the enzyme has been implicated in various DNA transactions (replication, transcription and recombination ) .
• Purified mammalian topoisomerase I relaxes positively-supercoiled as well as negatively- supercoiled DNA in a mechanism which involves the transient breakage of one of the two DNA strands and the formation of a covalent topoisomerase I-DNA complex. In this complex, the enzyme is covalently linked to the 3 ' -phosphoryl end of the broken DNA backbone.
• topoisomerase I enzyme levels were on average higher in cancerous tissue, e. g. , surgical specimens of colorectal carcinoma, in comparison to the enzyme level in normal mucosa (Hsiang, Y.-H., et al . , Proc Ann Meet of the Amer. Assoc. Cancer Res . 29:172 (1988) Abstract. Although it was stated that topoisomerase I could be considered as an alternative target in chemotherapy of this (colorectal carcinoma) disease, no disclosure or suggestion at all was made as to any specific topoisomerase I interacting drugs.
• the invention provides methods for inhibiting colon cancer in mammals by administering to the mammal in need thereof of an effective amount of a compound of formula I .
• R 1 and R 3 are independently hydrogen
• R 2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; and pharmaceutically acceptable salts and solvates thereof,
• the current invention concerns the discovery that a select group of 2-phenyl-3-aroylbenzothiophenes (benzothiophenes) , those of formula I, are useful for inhibiting colon cancer.
• the methods of use provided by this invention are practiced by administering to a human in need thereof a dose of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, that is effective to inhibit colon cancer.
• the term "inhibit” includes its generally accepted meaning which includes prohibiting, preventing, restraining, and slowing, stopping, or reversing progression, severity, or a resultant symptom or effect.
• Raloxifene a compound of this invention wherein it is the hydrochloride salt of a compound of formula 1, R 1 and R 3 are hydrogen and R 2 is 1-piperidinyl, is a nuclear regulatory molecule.
• Raloxifene has been shown to bind to the estrogen receptor and was originally thought to be a molecule whose function and pharmacology was that of an anti-estrogen in that it blocked the ability of estrogen to activate uterine tissue and estrogen dependent breast cancers. Indeed, raloxifene does block the action of estrogen in some cells; however in other cell types, raloxifene activates the same genes as estrogen does and displays the same pharmacology, e.g., osteoporosis, hyperlipidemia. As a result, raloxifene has been referred to as an anti-estrogen with mixed agonist-antagonist properties.
• the compound is formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes.
• the compounds can be administered transdermally, and may be formulated as sustained release dosage forms and the like.
• the compounds used in the methods of the current invention can be made according to established procedures, such as those detailed in U.S. Patent Nos. 4,133,814, 4,418,068, and 4,380,635 all of which are incorporated by reference herein. In general, the process starts with a benzo[b] hiophene having a 6-hydroxyl group and a 2- (4- hydroxyphenyl) group.
• Optionally substituted phenyl includes phenyl and phenyl substituted once or twice with Ci-C ⁇ alkyl, C 1 -C 4 alkoxy, hydroxy, nitro, chloro, fluoro, or tri (chloro or fluoro)methyl .
• the compounds used in the methods of this invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention.
• Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like.
• Salts derived from organic acids such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used.
• Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoa e, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, ⁇ -hydroxybutyrate, butyne-1, 4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogen
• the pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid.
• the reactants are generally combined in a mutual solvent such as diethyl ether or benzene.
• the salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
• Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates, as well as aliphatic and primary, secondary and tertiary amines, aliphatic diamines.
• Bases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, methylamine, diethylamine, ethylene diamine and cyclohexylamine.
• the pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
• compositions can be prepared by procedures known in the art.
• the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like.
• excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid
• the compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like.
• the formulations can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time.
• the coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
• the particular dosage of a compound of formula I required to inhibit colon cancer, or any other use disclosed herein, and according to this invention will depend upon the severity of the condition, the route of administration, and related factors that will be decided by the attending physician.
• accepted and effective daily doses will be from about 0.1 to about 1000 mg/day, and more typically from about 50 to about 200 mg/day.
• Such dosages will be administered to a subject in need thereof from once to about three times each day, or more often as needed to effectively inhibit colon cancer. It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the administration of pharmaceuticals bearing a basic group, such as the piperidino ring. It is also advantageous to administer such a compound by the oral route. For such purposes the following oral dosage forms are available.
• the ingredients are blended, passed through a No . 45 mesh U. S . sieve , and f illed into hard gelatin capsules .
• Silicone fluid 350 centistokes 1 .7 Formulation 3 Raloxifene capsule
• a tablet formulation is prepared using the ingredients below: Formulation 6 : Tablets
• the components are blended and compressed to form tablets ,
• tablets each containing 0.1 - 1000 mg of active ingredient are made up as follows :
• the active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
• the solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve.
• the granules so produced are dried at 50°-60° C and passed through a No. 18 mesh U.S. sieve.
• the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
• Suspensions each containing 0.1 - 1000 mg of medicament per 5 mL dose are made as follows: Formulation 8: Suspensions
• the medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste.
• the benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
• Desmoid tumors are rare non metastatic tumors of fibrous origin. Clinical correlates suggest that steroid hormones may have a role in the natural history of these tumors: it is predominantly seen in female patients of child-bearing age and regression of these tumors have been associated with menopause or with antiestrogen therapy. The aim of this work was to identify estrogen receptors in desmoid tumor primary cells, and to evaluate the effect of a compound of formula I on desmoid cells in primary culture.
• FAP Familial Adenomatous Polyposis
• Compound Ia is a compound of formula I wherein R 2 is pyrrolidino, and R 1 and R 3 are hydrogen. Binding studies are performed using intact cells. Desmoid cells are plated on 6-well plates in growth medium (Coon's modified Ham's F12 supplemented with 10% FCS) . After 24 hours, the growth medium is substituted with steady state medium without phenol red, and cells are maintained in starvation for 24 hours. Then cells are incubated for one hour with 1 ml of medium without phenol red containing 25 mM HEPES and 0.5% EtOH (binding buffer) and increasing concentrations (0.05- 10 nM) of [3H]17SE2 with or without a 500-fold excess of unlabeled 17SE2 and
• the pulverized tissue is homogenized with two 10-sec burst in a polytron homogenizer separated by a 30-sec cooling period in the following buffer: 10 mM Tris-HCl, 5 mM EDTA, 10 mM sodium molybdate, 10 mM dithiothreitol, 10% glycerol (v/v) , pH 7.4.
• the homogenate is centrifuged at 7000 g for 20 min and the pellet is discarded, the supernatant was recentrifuged at 105000 g for 60 min to obtain cytosol for estrogen receptor analysis. Cytosol is diluted to 1-2 mg protein/ml. Cytosol protein is determined according to the method of Bradford.
• cytosol is incubated for 16 hr at 4°C over a concentration range of 0.05-5 nM of [ 3 H]17 ⁇ E with or without a 500-fold excess of unlabeled 17SE 2 and Compound Ia.
• ER binding affinity and binding capacity are evaluated by Scatchard analysis.
• Cells are plated on 6 well plates at a density of 8xl0 4 cell for well in growth medium. After 24 hours, the cells are stimulated in growth medium without phenol red supplemented with 0.1% DMF, 0.1% EtOH, and different concentrations of Compound Ia (2xlO" 5 M, 10" 5 M, 5xl0" 6 M, 10" 6 M) .
• Cells are incubated six days, detached with trypsin/ethylenediamine tetracetic acid solution and then the growth is evaluated by counting to the microscope.
• the same method is used for colon cancer primary fibroblasts cell line and for HCT8 cell line: this line is cultured in RPMI and incubated 4 days after stimulation.
• Collagen type I in culture media and cell layers are measured using an enzyme-linked immunoassay (ELISA) . Briefly, cells are incubated for 24 hrs in supplement-free Coon's modified Ham F12 medium containing 50 ⁇ g/ml ascorbic acid and lOO ⁇ g/ml Saminopropionitryl fumarate.
• ELISA enzyme-linked immunoassay
• Culture media are harvested and appropriately diluted in 0.1 M carbonate/bicarbonate buffer (pH 9.6) and then used for coating the ELISA plates, overnight at 4°C ELISA plates are incubated 1.5 hrs at 37°C in PBS containing 5% of milk powder (PBS Blotto) to saturate non specific binding sites, 2 hrs at 37°C with PBS Blotto containing the specific polyclonal antibody, and 1.5 hrs at 37°C in PBS Blotto containing goat antirabbit igG-alkaline phosphatase conjugated complex (Sigma Chemical Co., St. Louis, MO) . Samples are then exposed to 10% diethanolamine
• Desmoid cells are inhibited in a dose-dependent fashion by Compound Ia at concentrations of 10 ⁇ 5 M, 5xlO ⁇ 6 M, 10 -6 M, with maximal inhibitory effect at 10" 5 M concentration (Table 4) .
• Compound Ia is able to displace 17 ⁇ E 2 binding to desmoid tissue only at very high concentrations (500-fold excess) .
• Compound Ia is able to significantly inhibit desmoid cell proliferation at micromolar concentrations. In addition, at similar concentrations the compound inhibits the proliferation of epithelial and fibroblastic cells derived from human colon cancer.
• Type I collagen production is also significantly reduced in desmoid cell in primary culture by the Compound la.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Gastroenterology & Hepatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Pyrrole Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26308709

Family Applications (1)

Country Status (19)

Citations (1)

Family Cites Families (2)

• 1997
  • 1997-01-22 ID IDP970182A patent/ID15917A/id unknown
  • 1997-01-24 YU YU2397A patent/YU2397A/sr unknown
  • 1997-01-24 AR ARP970100300A patent/AR010978A1/es unknown
  • 1997-01-25 TW TW086100832A patent/TW446560B/zh not_active IP Right Cessation
  • 1997-01-27 EP EP97906587A patent/EP0921799A4/en not_active Withdrawn
  • 1997-01-27 IL IL12552197A patent/IL125521A/en not_active IP Right Cessation
  • 1997-01-27 AU AU21239/97A patent/AU707892B2/en not_active Ceased
  • 1997-01-27 CN CN97191791A patent/CN1209745A/zh active Pending
  • 1997-01-27 CZ CZ982354A patent/CZ235498A3/cs unknown
  • 1997-01-27 BR BR9700778A patent/BR9700778A/pt active Search and Examination
  • 1997-01-27 KR KR1019980705775A patent/KR19990082054A/ko not_active Application Discontinuation
  • 1997-01-27 WO PCT/US1997/002286 patent/WO1997026877A1/en not_active Application Discontinuation
  • 1997-01-27 NZ NZ331105A patent/NZ331105A/en unknown
  • 1997-01-27 PL PL97328147A patent/PL328147A1/xx unknown
  • 1997-01-27 EA EA199800677A patent/EA001104B1/ru not_active IP Right Cessation
  • 1997-01-27 JP JP9527132A patent/JP2000503994A/ja active Pending
  • 1997-01-28 CO CO97003856A patent/CO4761062A1/es unknown
• 1998
  • 1998-07-27 MX MX9806036A patent/MX9806036A/es unknown
  • 1998-07-27 NO NO983451A patent/NO983451D0/no not_active Application Discontinuation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events